Pet Medication Innovation Watch

BRAVECTO® QUANTUM

BRAVECTO® QUANTUM / fluralaner for extended-release injectable suspension

Recently FDA-confirmed FDA-confirmed FDA-confirmed

FDA-confirmed status means Roxee found public approval or market-status evidence. Ask your veterinarian whether this option applies to your pet.

Veterinary professional?

What this means

Owner summary

This is a public veterinary medicine update Roxee is tracking with source-backed evidence and availability labels.

Do not start, stop, or switch medicine without your veterinarian.
Development-stage products are not shown as available unless FDA approval or marketed evidence is public.
Ask your veterinarian about currently approved options for parasite prevention and treatment.

Vet view

Technical note

No vet-facing summary has been approved for this innovation record yet.

Regulator: FDA/CVM
Pathway: NADA/ANADA/CNADA
FDA application: 141599

Regulatory timeline

Public stage evidence

Only supported or current stages are highlighted.

1 Early research signal
2 Company-disclosed development
3 FDA-CVM development path disclosed
4 Protocol concurrence disclosed
5 Pivotal study planned
6 Pivotal study recruiting
7 Pivotal study completed
8 Technical section submitted
9 Technical section complete
10 All major technical sections complete
11 Administrative NADA/CNADA submitted
12 FDA approved
13 Conditionally approved
14 Available / marketed

What changed

Latest public update

Date detected: May 19, 2026
Stage: FDA approved
Reason: MIW source adapter refresh

Owner-safe interpretation

Availability

FDA-confirmed status means Roxee found public approval or market-status evidence. Ask your veterinarian whether this option applies to your pet.

Expected availability: FDA approved, launch unclear

Evidence

Source-backed record

2 items shown

BRAVECTO® QUANTUM FDA recent animal drug approval FDA approval / Animal Drugs @ FDA · Primary source 100/100

Source: FDA Recent Animal Drug Approvals
Observed: May 19, 2026
Supports: FDA approved

Kills adult fleas and for the treatment and prevention of flea infestations ( Ctenocephalides felis ); for the treatment and control of tick infestations [ Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick)] for 12 months in dogs and puppi...

View source evidence

BRAVECTO® QUANTUM FDA recent animal drug approval FDA approval / Animal Drugs @ FDA · Primary source 100/100

Source: FDA Recent Animal Drug Approvals
Observed: May 19, 2026
Supports: FDA approved

This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (Asian longhorned tick) and Amblyomma maculatum (Gulf Coast tick) infestations for 12 months in dogs and puppies 6 months of age and older.

View source evidence